High-dose LT-02 meets ulcerative colitis endpoint

Lipid Therapeutics GmbH (Heidelberg, Germany) said high-dose LT-02 given four times per day met the primary endpoint in a Phase IIb trial to treat mesalazine-refractory ulcerative colitis. A 0.8 g dose of LT-02 significantly reduced Simple Clinical Colitis Activity Index (SCCAI) scores from baseline to week 12 vs. placebo (51% vs. 33%, p<0.05). The 0.2 and 0.4 g doses of the compound given four times per day missed the endpoint. The double-blind, international trial enrolled 156 patients. Full data will be presented at the United European Gastroenterology Week meeting in Stockholm in October. ...